BridgeBio Oncology Therapeutics, Inc.
BBOT
$9.71
$0.879.84%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 94.79% | 9.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 26.07% | 49.76% | |||
| Operating Income | -26.07% | -49.76% | |||
| Income Before Tax | -30.30% | -42.82% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -30.30% | -42.82% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -30.30% | -42.82% | |||
| EBIT | -26.07% | -49.76% | |||
| EBITDA | -26.05% | -49.92% | |||
| EPS Basic | 71.22% | 56.20% | |||
| Normalized Basic EPS | 71.22% | 56.20% | |||
| EPS Diluted | 71.22% | 56.20% | |||
| Normalized Diluted EPS | 71.22% | 56.20% | |||
| Average Basic Shares Outstanding | 352.77% | 226.14% | |||
| Average Diluted Shares Outstanding | 352.77% | 226.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||